E-7820 clinical trials
Also written E7820.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses E-7820 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- E7820
- 5
Studies by the year they started
6 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Often tested with
Tested in the same studies.
Bevacizumab (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Studies
Open first, then newest update. How each study uses E-7820 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT05024994Written as E7820
- FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal CancerTerminatedPhase 1/2Eisai Inc.NCT01133990Written as E7820
- An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid TumorsCompletedPhase 1Eisai Inc.NCT01773421Written as E7820
- Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal CancerTerminatedPhase 1/2Eisai Inc.NCT01347645Written as E7820
- A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid TumorsCompletedPhase 2Eisai Inc.NCT00309179Written as E7820 plus cetuximab
- Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or LymphomaCompletedPhase 1Eisai Inc.NCT00078637Written as E7820
Codes
What other systems call E-7820 · ClinicalTrials.gg INT004489
- UNII (FDA) TVH5K7949NE-7820Confirmed FDA, Wikidata
- Wikidata Q27290435E-7820Confirmed FDA, Wikidata
- DrugBank DB12505One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TVH5K7949N | E-7820 | Confirmed FDA, Wikidata |
| Wikidata | Q27290435 | E-7820 | Confirmed FDA, Wikidata |
| DrugBank | DB12505 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.